Esperion Therapeutics ESPR Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's other income (expense)?
- Esperion Therapeutics (ESPR) reported other income (expense) of $1.18M in Q1 2026.
- How has Esperion Therapeutics's other income (expense) changed year-over-year?
- Esperion Therapeutics's other income (expense) increased by 10.4% year-over-year, from $1.07M to $1.18M.
- What is the long-term trend for Esperion Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Esperion Therapeutics's other income (expense) has grown at a -3.2% compound annual growth rate (CAGR), from $3.98M to $3.49M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.